25 May 2013
Keywords: crucell, discusses, corporate, strategy, product, pipeline, analyst
Article | 08 May 2006
Dutch biotechnology company Crucell, a specialist in the development of vaccines and antibodies for the treatment of infectious diseases, held
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
8 May 2006
15 May 2006
24 May 2013
© 2013 thepharmaletter.com